Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 13.06.19
Views: 556

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

Dr Jonathan Rosenberg speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the CALGB 90601 trial, which compares gemcitabine and cisplatin (GC) with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

He explains the methods used by the phase III randomised, double-blind, placebo control trial and reports that there was little to no change in overall survival, progression free survival or tolerability by adding bevacizumab to GC chemotherapy.

Dr Rosenberg concludes that while these results did not impact standard practice, they hope to continue learning from the trial by looking at translational studies around angiogenesis signatures, DNA damage repair mutations, and expression profiling to identify immune sub-types.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation